Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03045029 · ClinicalTrials.gov registry record
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
A clinical trial of Pulmonary Arterial Hypertension, sponsored by United Therapeutics.
- Active
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT03045029 is a study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by United Therapeutics. The registered enrollment target is 300 participants, below the 458-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT03045029, a study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by United Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation
Conditions Studied
Interventions
- DRUG Oral treprostinil
Study Locations (20)
Florida
- Lung Associates PA - Bradenton
- University of Florida Clinical Research Center - Gainesville
- St. Vincent's Lung, Sleep, and Critical Care Specialists - Jacksonville
- AdventHealth Orlando - Orlando
- Central Florida Pulmonary Group, P.A. - Orlando
- USF South Florida Heart Health - Tampa
- Cleveland Clinic Florida - Weston
California
- University of California - San Francisco - Fresno
- University of Southern California - Keck Medical Center - Los Angeles
- Paloma Medical Group - San Juan Capistrano
- Santa Barbara Pulmonary Associates - Santa Barbara
- Harbor UCLA Medical Center - Torrance
Colorado
- Aurora Denver Cardiology Associates - Aurora
- Pueblo Pulmonary Associates - Pueblo
Georgia
- Piedmont Healthcare/Research - Austell
Illinois
- Loyola University Chicago - Chicago
Indiana
- Saint Vincent Hospital and Health Services - Indianapolis
Iowa
- University Of Iowa Hospital and Clinics - Iowa City
Kentucky
- University of Louisville Physicians Outpatient Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2017-07-18 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03045029
The ClinicalTrials.gov registry entry for NCT03045029 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 458-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (34% lower). The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Oral treprostinil is the first listed.
NCT03045029 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03045029 about?
NCT03045029 is a clinical study titled "ADAPT - A Patient Registry of the Real-world Use of Orenitram®". This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation
What is the current status of trial NCT03045029?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2017-07-18. Estimated completion is 2025-12.
What conditions does trial NCT03045029 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT03045029?
The interventions under investigation include: Oral treprostinil (DRUG).
Who is sponsoring clinical trial NCT03045029?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03045029 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.